HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era

Podrobná bibliografie
Hlavní autoři:	Orkin, C, Montoto, S, Shaw, K, Okosun, J, Gandhi, S, Fields, P, Wilson, A, Shanyinde, M, Cwynarski, K, Marcus, R, De Vos, J, Young, A, Tenant-Flowers, M, Johnson, M, Chilton, D, Gribben, J, Bower, M
Médium:	Journal article
Vydáno:	2012

HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era
Autor: Montoto, S, a další
Vydáno: (2011)

HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Autor: Montoto, S, a další
Vydáno: (2012)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
Autor: Bhanu Vakkalanka, a další
Vydáno: (2011-01-01)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
Autor: Adam F. Binder, a další
Vydáno: (2017-10-01)

Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD
Autor: Diego Villa, a další
Vydáno: (2018-12-01)

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
Autor: Subbiah Vivek, a další
Vydáno: (2007-11-01)

S202: CHILDBEARING AMONG CLASSICAL HODGKIN LYMPHOMA SURVIVORS TREATED WITH BEACOPP AND ABVD IN SWEDEN, DENMARK, AND NORWAY
Autor: J. P. Entrop, a další
Vydáno: (2022-06-01)

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study
Autor: Paolo Strati, a další
Vydáno: (2019-02-01)

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
Autor: Ryo Yonezawa, a další
Vydáno: (2023-01-01)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
Autor: Schwenkglenks Matthias, a další
Vydáno: (2010-08-01)

Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
Autor: Camille Cotteret, a další
Vydáno: (2020-04-01)

Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort studyResearch in context
Autor: Marriam Mponda, a další
Vydáno: (2024-03-01)

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation
Autor: Rebecca J. DeBoer, a další
Vydáno: (2020-11-01)

Advanced Hodgkin's lymphoma: results in 216 patients treated with ABVD in Brazil Linfoma de Hodgkin em estádio avançado: resultados do tratamento em 216 pacientes tratados com ABVD no Brasil
Autor: Luciana Britto, a další
Vydáno: (2010-01-01)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
Autor: Min Hu, a další
Vydáno: (2023-08-01)

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
Autor: Joshua P. Entrop, a další
Vydáno: (2022-10-01)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
Autor: Vojin Vukovic, a další
Vydáno: (2023-08-01)

Clinical profile and outcome of classical Hodgkin lymphoma treated with ABVD protocol at Homi Bhabha Cancer Hospital Varanasi
Autor: NIKITA SINGH, a další
Vydáno: (2022-01-01)

A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD
Autor: Chakraborty R, a další
Vydáno: (2015-03-01)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
Autor: Heidi Mocikova, a další
Vydáno: (2022-10-01)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
Autor: Arun Seshachalam, a další
Vydáno: (2019-12-01)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
Autor: Jillian R. Gunther, a další
Vydáno: (2020-07-01)

Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.
Autor: Greaves, P, a další
Vydáno: (2013)

P033 (0007) SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET
Vydáno: (2018-10-01)

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
Autor: Marc P. E. André, a další
Vydáno: (2020-09-01)

Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD
Autor: Alessandro Cellini, a další
Vydáno: (2024-09-01)

Brentuximab vedotin followed by ABVD +/− radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study
Autor: Massimo Federico, a další
Vydáno: (2016-04-01)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
Autor: Tawatchai Suwanban, a další
Vydáno: (2023-08-01)

P1081: PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL
Autor: A. Pavlovsky, a další
Vydáno: (2022-06-01)

Influência do CD 20 na refratariedade do linfoma de Hodgkin clássico ao tratamento inicial com o esquema ABVD, no Ceará, Brasil Influence of CD 20 antigen expression in the refractoriness of classical Hodgkin lymphoma in the first line treatment with ABVD protocol in Ceará state, Brazil
Autor: Rogério Pinto Giesta, a další
Vydáno: (2009-06-01)

FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin’s disease-a useful tool for monitoring pulmonary toxicity and disease activity
Autor: T. Buchler, a další
Vydáno: (2007-11-01)

A comparison of clinical profile and treatment outcome of Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era
Autor: Mercy M. Mbai, a další
Vydáno: (2024-07-01)

Pilot study of lung cancer screening for survivors of Hodgkin lymphoma
Autor: Rachel Broadbent, a další
Vydáno: (2023-11-01)

P030 (0143) ONCE-A-CYCLE VS. DAILY G-CSF IN EARLY-UNFAVORABLE STAGES OF HODGKIN LYMPHOMA TREATED WITH BEACOPP ESCALATED FOLLOWED BY ABVD
Vydáno: (2018-10-01)

P1082: SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA
Autor: N. L. Fiad, a další
Vydáno: (2022-06-01)

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY
Autor: Ercole Brusamolino, a další
Vydáno: (2012-04-01)

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY
Autor: Ercole Brusamolino, a další
Vydáno: (2014-08-01)

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY
Autor: Ercole Brusamolino, a další
Vydáno: (2012-01-01)

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY
Autor: Ercole Brusamolino, a další
Vydáno: (2014-08-01)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
Autor: Michael Dickinson, a další
Vydáno: (2023-08-01)

HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era

Podobné jednotky

Podobné jednotky